Overcoming the PAM Sequence Bottleneck

24 concepts19 papers1 proposal

The CRISPR-Cas system is often described as a pair of "molecular scissors," but these scissors cannot cut just anywhere. To bind and cleave DNA, most Cas enzymes require a specific, short sequence adjacent to the target site known as a Protospacer Adjacent Motif (PAM). While the most common enzyme, SpCas9, recognizes the simple NGG motif, this requirement creates significant "blind spots" across the genome. If a specific mutation or regulatory element lacks a nearby PAM, it remains effectively un-editable.

Recent research has focused on breaking this bottleneck by discovering and engineering enzymes with flexible, relaxed, or entirely new PAM requirements to achieve universal genomic accessibility.

The Constraint of Genomic Blind Spots

The PAM acts as a critical recognition signal that allows the Cas protein to interrogate DNA without unwinding the entire double helix. However, as Abudayyeh et al. note, this requirement significantly limits the range of targetable sites. For applications requiring extreme precision—such as base editing a single pathogenic SNP or inserting a fluorescent tag at a specific protein terminus—the absence of a PAM within a narrow "activity window" can render the experiment impossible.

This limitation is particularly acute in specific genomic contexts:

  • AT-Rich Regions: Standard enzymes like SpCas9 are biased toward G-rich motifs. Lee et al. point out that this leaves AT-rich regions of the human genome largely inaccessible.
  • Non-Coding and Regulatory Elements: Mapping the "dark matter" of the genome requires high-density targeting. Cheng et al. found that NGG-PAM biases in library generation can limit the functional mapping of non-coding regions.
  • Organism-Specific Constraints: In organisms like Saccharomyces cerevisiae, Wang argues that strict PAM requirements hinder the precise positioning of regulatory tools within promoter regions.

Expanding the Toolbox via Natural Orthologs

One strategy to overcome these limits is to look toward the natural diversity of CRISPR systems in the bacterial world. By screening uncharacterized Cas orthologs, researchers have identified enzymes that naturally recognize different or more flexible PAMs.

For instance, Zetsche et al. identified Mb3Cas12a, which recognizes a relaxed TTN motif compared to the standard TTTV, significantly increasing targetable sites. Similarly, Liu et al. characterized SeqCas9, an ortholog that recognizes a highly flexible NNG PAM, combining broad targeting range with high-fidelity performance. These natural variants provide a broader "palette" of docking sequences, allowing researchers to choose the enzyme that best fits the local sequence of their target gene.

Engineering Universal Accessibility

Beyond discovering natural variants, researchers are using protein engineering to "relax" the PAM requirements of established enzymes. This involves modifying the PAM-interacting (PI) domain of the protein to recognize a wider array of DNA sequences.

A prominent example is the development of chimeric enzymes. Zhao et al. engineered SpRYc, a hybrid enzyme that combines broad PAM recognition with high efficiency, enabling the correction of previously "un-editable" disease mutations. In another approach, Lee et al. created iSpyMac by grafting the PI domain of a Streptococcus macacae Cas9 onto a standard scaffold, specifically to target adenine dinucleotide PAMs (NAAN), opening up nearly 20% more of the human genome.

The future of this field may lie in generative design. Schmitt demonstrated that deep learning models like RecGen can "hallucinate" functional designer-recombinases for entirely new DNA targets, potentially bypassing the need for laborious lab-based evolution.

Why Target Flexibility Matters

The drive toward PAM-flexibility is not just a technical exercise; it is essential for the transition of CRISPR from a research tool to a clinical reality. As Li et al. explain in the context of precision oncology, the ability to target specific mutations or regulatory elements is paramount for personalized immunotherapy and diagnostics.

In diagnostic applications, Greensmith et al. highlight that if a clinically relevant mutation lacks a nearby PAM, the detection system cannot be easily adapted. By removing these sequence-dependent barriers, researchers are turning the genome from a collection of restricted zones into a fully programmable landscape.

Key Foundational Work

Imaging Specific Genomic DNA in Living Cells (2016) — contributed 2 concept elements to this direction.
A Survey of Genome Editing Activity for 16 Cas12a Orthologs (2019) — contributed 1 concept elements to this direction.
Structural basis for the promiscuous PAM recognition by Corynebacterium diphtheriae Cas9 (2019) — contributed 1 concept elements to this direction.
History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 19 papers
  2. Version 1 · 2026-10-04 · 23 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_pam_sequence_restriction_1cbc27f1,
  title = {PAM sequence restriction},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/pam-sequence-restriction/rdr_1cbc27f1593b47baaa645cc18b09516e},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-22},
}

This exact version (version 2, frozen text):

@misc{lacuna_pam_sequence_restriction_1cbc27f1_v2,
  title = {PAM sequence restriction},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/pam-sequence-restriction/rdr_1cbc27f1593b47baaa645cc18b09516e/v/2},
  note = {Version 2, frozen 2026-10-04. Accessed 2026-11-22},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake